“UBS sees Hong Kong as an ideal IPO market due to the opportunities it offers for mainland investors,” says a UBS spokesperson. With the recent allowance for mainland trading of Hong Kong-listed international firms, UBS is poised to assist companies seeking dual listings or listing solely in Hong Kong.
Featuring in tours to promote Hong Kong’s IPO advantages, UBS aims to attract international listings to HKEX. Saudi firms, including Aramco, now have the option of secondary listings in Hong Kong.
Despite slipping in global rankings, Hong Kong is making a comeback with over 100 listing applications in the pipeline. With a recent market rally and favorable policies from the CSRC, including support for mainland companies listing in Hong Kong, UBS predicts a strong IPO market recovery.
UBS, ranked second in underwriting equity fundraising, anticipates total funds raised in Hong Kong to reach up to US$6 billion this year, with even more expected next year.
With upcoming blockbuster deals and focus on technology firms like QuantumPharm, UBS is confident in the future of Hong Kong’s IPO market.